Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.66 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218558 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL12426114 | 0.83 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL17480498 | 0.83 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL12426208 | 0.83 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL12662684 | 0.83 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL17480519 | 0.81 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL1853238 | 0.80 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Ym-543 Free Acid SCHEMBL14339156 | 0.80 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Ym-543 Free Acid SCHEMBL17034637 | 0.80 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Ym-543 Free Acid SCHEMBL10046215 | 0.80 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.